Australia: High Court delivers judgment in long-running rosuvastatin patent dispute

Last Updated: 7 September 2015
Article by Andrew Rankine
Focus: AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30
Services: Intellectual Property & Technology
Industry Focus: Life Sciences & Healthcare

The High Court of Australia today delivered its much anticipated judgment in patent litigation relating to AstraZeneca's blockbuster lipid-lowering drug, Crestor® (rosuvastatin).1

In long-running court proceedings, generic pharmaceutical suppliers including Apotex, Watson (subsequently named Actavis) and Ascent challenged the validity of a number of Australian patents owned by AstraZeneca (AZ) relating to rosuvastatin. At issue before the High Court was the validity of a patent covering methods of treating patients suffering raised cholesterol levels by administering once-daily rosuvastatin at a low starting dose of 5 or 10 mg (low-dose patent).

All five members of the High Court hearing this case upheld the finding of the Full Federal Court that AZ's low-dose patent was invalid for obviousness, or lack of inventive step.

What the High Court decided

The High Court's judgment provides important guidance on the approach to be taken when a court is called upon to decide whether or not the subject matter claimed in a patent involved an inventive step.

Under Australia's Patents Act 1990 (Cth) (Act) as it applies to the low-dose patent, the answer to that question depends upon whether the claimed subject matter would have been obvious to a notional skilled person in light of the common general knowledge (CGK) in their field. The Act permits regard to be had to documents, such as scientific articles and earlier patents, not forming part of the CGK that a skilled person could reasonably be expected to have "ascertained, understood and regarded as relevant". Importantly, under the version of the Act applicable to the low-dose patent, such documents may not be combined to establish obviousness. Each must be considered separately.

In finding the low-dose patent invalid for obviousness, the High Court rejected three key arguments advanced by AZ on the appeal.

First, AZ argued that the requirement to keep non-CGK documents separate applied not only when assessing the ultimate question of obviousness, but also at the antecedent stage of deciding whether a document would have been regarded as relevant by a skilled person. Rejecting that argument, the High Court confirmed that nothing in the Act precludes a skilled person from combining sources of information en route to concluding that a document is relevant to the problem addressed in a patent.

Secondly, AZ argued that where a literature review disclosed two or more alternative approaches to solving a problem, each of which would be considered relevant by a skilled person, it could not be "obvious" to adopt any one of them. That proposition was rejected by Chief Justice French, and in the joint judgment of Justices Gageler and Keane: if the claimed invention is obvious in light of CGK plus any one of several relevant documents, the patent will be held invalid.

Thirdly, AZ argued that the key document relied upon by the generic parties for their obviousness case failed to disclose the dosages of rosuvastatin claimed in the low-dose patent, and did not provide clinical trial data that a skilled person would require to identify a suitable starting dose. Rejecting that argument, the High Court pointed to expert evidence establishing that the relevant dosages would be identified through routine trials that a skilled person would conduct with an expectation of success in light of the document in question.

What the High Court did not decide

In their submissions to the High Court, the parties raised a number of other significant legal issues which, in the circumstances, the Court found it unnecessary to decide. In particular, the High Court found it unnecessary to address the question of whether or not, in separate litigation relating to Sanofi-Aventis' anti-clotting drug Plavix® (clopidogrel), the Full Federal Court had adopted the correct "starting point" when assessing obviousness.2 That issue has significance for ongoing legal proceedings in which the Commonwealth is seeking compensation for losses it claims to have suffered when an interlocutory injunction granted to Sanofi-Aventis delayed the market entry of generic clopidogrel products in Australia.


Today's decision of the High Court is highly significant for the parties to the Crestor® patent litigation. The generic parties, including Apotex, Watson (subsequently named Actavis) and Ascent could be expected to now seek compensation for losses incurred during the period when their rosuvastatin products were held off the Australian market by an interlocutory injunction granted to AZ. It is conceivable that the Commonwealth may also decide to seek compensation in relation to additional costs to the Pharmaceutical Benefits Scheme during the period for which the interlocutory injunction remained in force.

The decision also has broader significance for Australian law on obviousness, which is frequently a critical issue in patent disputes. In the course of today's judgment, Chief Justice French emphasised that the notional "skilled person", by reference to whom obviousness is assessed, is simply a tool for analysis and should not be made unnecessarily complicated by reference to "human" characteristics. Further, Justices Gageler and Keane pointedly noted that the plain and ordinary meaning of statutory language is not to be ignored or diminished simply because that language relates to intellectual property rights.


1AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30.
2Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.